Medpace Holdings Inc. (MEDP)
Why Medpace (MEDP) Dipped More Than Broader Market Today
Medpace (MEDP) closed at $530.19 in the latest trading session, marking a -1.49% move from the prior day.
Medpace Growth Trends Show How CRO Demand Is Shifting in 2026
MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.
Medpace Stock Outlook Turns on Backlog Quality and Cancellations
MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
In the closing of the recent trading day, Medpace (MEDP) stood at $543.57, denoting a +2.64% move from the preceding trading day.
Medpace (MEDP) Advances While Market Declines: Some Information for Investors
Medpace (MEDP) reached $519.96 at the closing of the latest trading day, reflecting a +1.4% change compared to its last close.
Medpace (MEDP) Suffers a Larger Drop Than the General Market: Key Insights
Medpace (MEDP) closed the most recent trading day at $461.6, moving 1.26% from the previous trading session.
Why the Market Dipped But Medpace (MEDP) Gained Today
Medpace (MEDP) closed at $466.79 in the latest trading session, marking a +1.94% move from the prior day.
Medpace (MEDP) Stock Slides as Market Rises: Facts to Know Before You Trade
Medpace (MEDP) closed at $445.59 in the latest trading session, marking a -1.3% move from the prior day.
LH or MEDP: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH) or Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
Medpace: Off The Pace Here Amidst Continued Booking Softness
Medpace's shares have sharply declined following a disappointing quarterly earnings report. A soft start to the year raises concerns about Medpace's near-term growth trajectory and operational momentum. The earnings miss may prompt investors to reassess MEDP's valuation and forward expectations.
Medpace Holdings: Downgrade To 'Buy' As Revenue Growth Remains, But With Caution Ahead
Medpace Holdings is downgraded from 'Strong Buy' to 'Buy' due to rising backlog cancellations and elevated direct costs, despite robust revenue growth. MEDP delivered Q1 2026 revenue of $706.6M (+26.5% YoY) and beat both top- and bottom-line expectations, with strong Net New Business Awards growth. The Net Book-to-Bill ratio fell to 0.88x in Q1 2026, driven by the highest backlog cancellations in over a year, warranting caution.
Down 15.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Medpace (MEDP)
The heavy selling pressure might have exhausted for Medpace (MEDP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
